AbbVie said Q2 2024 net revenues rose to $14.462 billion, up 4.3% on a reported basis and 5.6% on an operational basis. GAAP diluted EPS was $0.77, down 32.5%, and adjusted diluted EPS was $2.65, down 8.9%.

1. 01

   AbbVie said Q2 2024 net revenues rose to $14.462 billion, up 4.3% on a reported basis and 5.6% on an operational basis. GAAP diluted EPS was $0.77, down 32.5%, and adjusted diluted EPS was $2.65, down 8.9%.

2. 02

   The company said Global Humira net revenues for Q2 fell to $2.814 billion, down 29.8% on a reported basis. It said Global Skyrizi net revenues rose 44.8% to $2.727 billion, and Global Rinvoq net revenues rose 55.8% to $1.430 billion.

3. 03

   The company said its GAAP operating margin for Q2 was 27.6% and its adjusted operating margin was 42.6%. It said acquired IPR&D and milestones expense was 6.5% of net revenues, and it cited this expense as having an unfavorable impact of $0.52 per share.

4. 04

   The company said it is raising its full-year 2024 adjusted diluted EPS guidance to $10.71 to $10.91 from $10.61 to $10.81. The guidance includes an unfavorable impact of $0.60 per share from acquired IPR&D and milestones expense incurred year to date through Q2.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.